Evidence map›Paper›PMID 25221669›Full record

ArticleMedChemComm2014

Understanding the Structural Requirements of Hybrid (S)-6-((2-(4-Phenylpiperazin-1-yl)ethyl)(propyl)amino)-5,6,7,8-tetrahydronaphthalen-1-ol and its Analogs as D2/D3 Receptor Ligands: A Three-Dimensional Quantitative Structure-Activity Relationship (3D QSAR) Investigation.

Gyan Modi, Horrick Sharma, Prashant S Kharkar, Aloke K Dutta

Abstract read
In one paragraph

Article in MedChemComm, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Identification of Novel Dopamine DMolecules (Basel, Switzerland) · 2022
    Article
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Gyan ModiDepartment of Pharmaceutical Sciences, Eugene Applebaum College of Pharmaceutical and Health Sciences (EACPHS), Wayne State University, Detroit, MI 48201. USA.
Horrick SharmaDepartment of Pharmaceutical Sciences, Eugene Applebaum College of Pharmaceutical and Health Sciences (EACPHS), Wayne State University, Detroit, MI 48201. USA.
Prashant S KharkarDepartment of Pharmaceutical Chemistry, SPP School of Pharmacy and Technology Management (SPPSPTM), SVKM's NMIMS, Mumbai-400 056. India.
Aloke K DuttaDepartment of Pharmaceutical Sciences, Eugene Applebaum College of Pharmaceutical and Health Sciences (EACPHS), Wayne State University, Detroit, MI 48201. USA.

Funding

Novel Neuroprotective Treatment for Parkinson's DiseaseR01NS047198 · NINDS · WAYNE STATE UNIVERSITY · PI DUTTA, ALOKE K · 2005 to 2015
$3.7M
NINDS NIH HHS R01 NS047198
6 · The paper itself

Abstract

To gain insights into the structural requirements for dopamine D2 and D3 agonists in the treatment of Parkinson's disease (PD) and to elucidate the basis of selectivity for D3 over D2 (D2/D3), 3D quantitative structure-activity relationship (3D QSAR) investigations using CoMFA (comparative molecular field analysis) and CoMSIA (comparative molecular similarity indices analysis) methods were performed on a series of 45 structurally related D2 and D3 dopaminergic ligands. Two alignment methods (atom-based and flexible) and two charge calculation methods (Gasteiger-Hückel and AM1) were used in the present study. Overall, D2 affinity and selectivity (D2/D3) models performed better with r

Indexed as

CoMFACoMSIAD2 affinityD3 affinityD3 selectivity

Identifiers

PMID25221669
PMCPMC4159175

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.